Effects of multiple daily injection therapy with humalog® mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus

Paris Roach, Shan Bai, Bernard Charbonnel, Agostino Consoli, Claudio Taboga, Antonio Tiengo, Geremia Bolli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Injection of insulin lispro (LP) before meals provides a more physiologic insulin activity profile than regular human insulin, but the relatively short duration of action of LP may allow the blood glucose (BG) level to increase during the late postprandial period (4-7 hours after meals) unless basal insulin is optimally replaced. One approach to basal insulin optimization has been to combine small doses of NPH with LP before meals. When used in a similar fashion, premixed, fixed-ratio insulin preparations containing LP and NPL (an LP-based intermediate-acting insulin) may provide the basis for an optimized basal-bolus insulin regimen. Objective: This study assessed mean late postprandial glycemic control during treatment with a premixed formulation consisting of a high proportion of LP (75% LP/25% NPL; H) and a premixed formulation consisting of a medium proportion of LP (50% LP/50% NPL; M). The H/M formulation was given before meals and was compared with treatment with preprandial LP + NPH (LP + N) in patients with type 1 diabetes mellitus (DM). Methods: This multicenter, randomized, open-label, 2-period crossover study was conducted at 4 centers in Italy and 1 center in France. Patients eligible for the study had type 1 DM, were ≥18 years of age, and had a glycosylated hemoglobin (HbA1c) <150% of the upper limit of normal. Patients were randomly assigned to 1 of 2 treatment sequences: LP self-mixed with NPH before meals plus NPH alone at bedtime for 8 weeks (LP + N) followed by preprandial H or M, plus NPH alone at bedtime for 8 weeks (H/M), or the opposite sequence. Assessments included 8-point self-monitored BG profiles, HbA 1c, and hypoglycemia (any sign or symptom of hypoglycemia or BG <3.0 mmol/L [<54.0 mg/dL]). The primary outcome measure was the late postprandial BG value, calculated as the mean of the combined prelunch (late postbreakfast), predinner (late postlunch), and bedtime (late postdinner) values. Results: A total of 89 patients with type 1 DM were enrolled (44 men, 45 women; mean [SD] age, 38.3 [12.8] years; mean [SD] body weight, 70.8 [11.6] kg; mean [SD] body mass index, 24.6 [3.0] kg/m2; mean [SD] duration of diabetes, 17.8 [10.5] years; mean HbA1c, 7.9% [0.88%]). The mean (SD) late postprandial BG values were similar between treatments (8.9 [2.1] mmol/L [160.3 (37.8) mg/dL] for H/M vs 9.0 [1.8] mmol/L [162.1 (32.4) mg/dL] for LP + N), as were the end point HbA1c values (7.8% [0.9%] for H/M vs 7.9% [0.8%] for LP + N). The rate of hypoglycemia was significantly higher during treatment with H/M, primarily because of episodes occurring between 12 PM and 6 PM, but was relatively low in both groups (mean/median rate per patient per 30 days: 2.87/2.14 for H/M and 2.11/1.07 for LP + N; P < 0.05). Conclusions: In this population of patients with type 1 DM, preprandial H/M provided an effective alternative regimen for prandial and basal insulin replacement. Late postprandial BG control, an indicator of basal insulin sufficiency, was similar to that achieved with an intensified regimen of LP + N injected separately before meals, and the end point HbA1c was similar between the 2 treatments.

Original languageEnglish
Pages (from-to)502-510
Number of pages9
JournalClinical Therapeutics
Volume26
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Insulin Lispro
Isophane Insulin
Type 1 Diabetes Mellitus
Injections
Meals
Insulin
Blood Glucose
Therapeutics
Hypoglycemia
Insulin, Regular, Human
Postprandial Period

Keywords

  • Insulin lispro mix75/25
  • Intensive insulin treatment

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of multiple daily injection therapy with humalog® mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. / Roach, Paris; Bai, Shan; Charbonnel, Bernard; Consoli, Agostino; Taboga, Claudio; Tiengo, Antonio; Bolli, Geremia.

In: Clinical Therapeutics, Vol. 26, No. 4, 04.2004, p. 502-510.

Research output: Contribution to journalArticle

Roach, Paris ; Bai, Shan ; Charbonnel, Bernard ; Consoli, Agostino ; Taboga, Claudio ; Tiengo, Antonio ; Bolli, Geremia. / Effects of multiple daily injection therapy with humalog® mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. In: Clinical Therapeutics. 2004 ; Vol. 26, No. 4. pp. 502-510.
@article{813f1f09b5a2488b92061eef11baf404,
title = "Effects of multiple daily injection therapy with humalog{\circledR} mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus",
abstract = "Background: Injection of insulin lispro (LP) before meals provides a more physiologic insulin activity profile than regular human insulin, but the relatively short duration of action of LP may allow the blood glucose (BG) level to increase during the late postprandial period (4-7 hours after meals) unless basal insulin is optimally replaced. One approach to basal insulin optimization has been to combine small doses of NPH with LP before meals. When used in a similar fashion, premixed, fixed-ratio insulin preparations containing LP and NPL (an LP-based intermediate-acting insulin) may provide the basis for an optimized basal-bolus insulin regimen. Objective: This study assessed mean late postprandial glycemic control during treatment with a premixed formulation consisting of a high proportion of LP (75{\%} LP/25{\%} NPL; H) and a premixed formulation consisting of a medium proportion of LP (50{\%} LP/50{\%} NPL; M). The H/M formulation was given before meals and was compared with treatment with preprandial LP + NPH (LP + N) in patients with type 1 diabetes mellitus (DM). Methods: This multicenter, randomized, open-label, 2-period crossover study was conducted at 4 centers in Italy and 1 center in France. Patients eligible for the study had type 1 DM, were ≥18 years of age, and had a glycosylated hemoglobin (HbA1c) <150{\%} of the upper limit of normal. Patients were randomly assigned to 1 of 2 treatment sequences: LP self-mixed with NPH before meals plus NPH alone at bedtime for 8 weeks (LP + N) followed by preprandial H or M, plus NPH alone at bedtime for 8 weeks (H/M), or the opposite sequence. Assessments included 8-point self-monitored BG profiles, HbA 1c, and hypoglycemia (any sign or symptom of hypoglycemia or BG <3.0 mmol/L [<54.0 mg/dL]). The primary outcome measure was the late postprandial BG value, calculated as the mean of the combined prelunch (late postbreakfast), predinner (late postlunch), and bedtime (late postdinner) values. Results: A total of 89 patients with type 1 DM were enrolled (44 men, 45 women; mean [SD] age, 38.3 [12.8] years; mean [SD] body weight, 70.8 [11.6] kg; mean [SD] body mass index, 24.6 [3.0] kg/m2; mean [SD] duration of diabetes, 17.8 [10.5] years; mean HbA1c, 7.9{\%} [0.88{\%}]). The mean (SD) late postprandial BG values were similar between treatments (8.9 [2.1] mmol/L [160.3 (37.8) mg/dL] for H/M vs 9.0 [1.8] mmol/L [162.1 (32.4) mg/dL] for LP + N), as were the end point HbA1c values (7.8{\%} [0.9{\%}] for H/M vs 7.9{\%} [0.8{\%}] for LP + N). The rate of hypoglycemia was significantly higher during treatment with H/M, primarily because of episodes occurring between 12 PM and 6 PM, but was relatively low in both groups (mean/median rate per patient per 30 days: 2.87/2.14 for H/M and 2.11/1.07 for LP + N; P < 0.05). Conclusions: In this population of patients with type 1 DM, preprandial H/M provided an effective alternative regimen for prandial and basal insulin replacement. Late postprandial BG control, an indicator of basal insulin sufficiency, was similar to that achieved with an intensified regimen of LP + N injected separately before meals, and the end point HbA1c was similar between the 2 treatments.",
keywords = "Insulin lispro mix75/25, Intensive insulin treatment",
author = "Paris Roach and Shan Bai and Bernard Charbonnel and Agostino Consoli and Claudio Taboga and Antonio Tiengo and Geremia Bolli",
year = "2004",
month = "4",
doi = "10.1016/S0149-2918(04)90052-5",
language = "English",
volume = "26",
pages = "502--510",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Effects of multiple daily injection therapy with humalog® mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus

AU - Roach, Paris

AU - Bai, Shan

AU - Charbonnel, Bernard

AU - Consoli, Agostino

AU - Taboga, Claudio

AU - Tiengo, Antonio

AU - Bolli, Geremia

PY - 2004/4

Y1 - 2004/4

N2 - Background: Injection of insulin lispro (LP) before meals provides a more physiologic insulin activity profile than regular human insulin, but the relatively short duration of action of LP may allow the blood glucose (BG) level to increase during the late postprandial period (4-7 hours after meals) unless basal insulin is optimally replaced. One approach to basal insulin optimization has been to combine small doses of NPH with LP before meals. When used in a similar fashion, premixed, fixed-ratio insulin preparations containing LP and NPL (an LP-based intermediate-acting insulin) may provide the basis for an optimized basal-bolus insulin regimen. Objective: This study assessed mean late postprandial glycemic control during treatment with a premixed formulation consisting of a high proportion of LP (75% LP/25% NPL; H) and a premixed formulation consisting of a medium proportion of LP (50% LP/50% NPL; M). The H/M formulation was given before meals and was compared with treatment with preprandial LP + NPH (LP + N) in patients with type 1 diabetes mellitus (DM). Methods: This multicenter, randomized, open-label, 2-period crossover study was conducted at 4 centers in Italy and 1 center in France. Patients eligible for the study had type 1 DM, were ≥18 years of age, and had a glycosylated hemoglobin (HbA1c) <150% of the upper limit of normal. Patients were randomly assigned to 1 of 2 treatment sequences: LP self-mixed with NPH before meals plus NPH alone at bedtime for 8 weeks (LP + N) followed by preprandial H or M, plus NPH alone at bedtime for 8 weeks (H/M), or the opposite sequence. Assessments included 8-point self-monitored BG profiles, HbA 1c, and hypoglycemia (any sign or symptom of hypoglycemia or BG <3.0 mmol/L [<54.0 mg/dL]). The primary outcome measure was the late postprandial BG value, calculated as the mean of the combined prelunch (late postbreakfast), predinner (late postlunch), and bedtime (late postdinner) values. Results: A total of 89 patients with type 1 DM were enrolled (44 men, 45 women; mean [SD] age, 38.3 [12.8] years; mean [SD] body weight, 70.8 [11.6] kg; mean [SD] body mass index, 24.6 [3.0] kg/m2; mean [SD] duration of diabetes, 17.8 [10.5] years; mean HbA1c, 7.9% [0.88%]). The mean (SD) late postprandial BG values were similar between treatments (8.9 [2.1] mmol/L [160.3 (37.8) mg/dL] for H/M vs 9.0 [1.8] mmol/L [162.1 (32.4) mg/dL] for LP + N), as were the end point HbA1c values (7.8% [0.9%] for H/M vs 7.9% [0.8%] for LP + N). The rate of hypoglycemia was significantly higher during treatment with H/M, primarily because of episodes occurring between 12 PM and 6 PM, but was relatively low in both groups (mean/median rate per patient per 30 days: 2.87/2.14 for H/M and 2.11/1.07 for LP + N; P < 0.05). Conclusions: In this population of patients with type 1 DM, preprandial H/M provided an effective alternative regimen for prandial and basal insulin replacement. Late postprandial BG control, an indicator of basal insulin sufficiency, was similar to that achieved with an intensified regimen of LP + N injected separately before meals, and the end point HbA1c was similar between the 2 treatments.

AB - Background: Injection of insulin lispro (LP) before meals provides a more physiologic insulin activity profile than regular human insulin, but the relatively short duration of action of LP may allow the blood glucose (BG) level to increase during the late postprandial period (4-7 hours after meals) unless basal insulin is optimally replaced. One approach to basal insulin optimization has been to combine small doses of NPH with LP before meals. When used in a similar fashion, premixed, fixed-ratio insulin preparations containing LP and NPL (an LP-based intermediate-acting insulin) may provide the basis for an optimized basal-bolus insulin regimen. Objective: This study assessed mean late postprandial glycemic control during treatment with a premixed formulation consisting of a high proportion of LP (75% LP/25% NPL; H) and a premixed formulation consisting of a medium proportion of LP (50% LP/50% NPL; M). The H/M formulation was given before meals and was compared with treatment with preprandial LP + NPH (LP + N) in patients with type 1 diabetes mellitus (DM). Methods: This multicenter, randomized, open-label, 2-period crossover study was conducted at 4 centers in Italy and 1 center in France. Patients eligible for the study had type 1 DM, were ≥18 years of age, and had a glycosylated hemoglobin (HbA1c) <150% of the upper limit of normal. Patients were randomly assigned to 1 of 2 treatment sequences: LP self-mixed with NPH before meals plus NPH alone at bedtime for 8 weeks (LP + N) followed by preprandial H or M, plus NPH alone at bedtime for 8 weeks (H/M), or the opposite sequence. Assessments included 8-point self-monitored BG profiles, HbA 1c, and hypoglycemia (any sign or symptom of hypoglycemia or BG <3.0 mmol/L [<54.0 mg/dL]). The primary outcome measure was the late postprandial BG value, calculated as the mean of the combined prelunch (late postbreakfast), predinner (late postlunch), and bedtime (late postdinner) values. Results: A total of 89 patients with type 1 DM were enrolled (44 men, 45 women; mean [SD] age, 38.3 [12.8] years; mean [SD] body weight, 70.8 [11.6] kg; mean [SD] body mass index, 24.6 [3.0] kg/m2; mean [SD] duration of diabetes, 17.8 [10.5] years; mean HbA1c, 7.9% [0.88%]). The mean (SD) late postprandial BG values were similar between treatments (8.9 [2.1] mmol/L [160.3 (37.8) mg/dL] for H/M vs 9.0 [1.8] mmol/L [162.1 (32.4) mg/dL] for LP + N), as were the end point HbA1c values (7.8% [0.9%] for H/M vs 7.9% [0.8%] for LP + N). The rate of hypoglycemia was significantly higher during treatment with H/M, primarily because of episodes occurring between 12 PM and 6 PM, but was relatively low in both groups (mean/median rate per patient per 30 days: 2.87/2.14 for H/M and 2.11/1.07 for LP + N; P < 0.05). Conclusions: In this population of patients with type 1 DM, preprandial H/M provided an effective alternative regimen for prandial and basal insulin replacement. Late postprandial BG control, an indicator of basal insulin sufficiency, was similar to that achieved with an intensified regimen of LP + N injected separately before meals, and the end point HbA1c was similar between the 2 treatments.

KW - Insulin lispro mix75/25

KW - Intensive insulin treatment

UR - http://www.scopus.com/inward/record.url?scp=2342471306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342471306&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(04)90052-5

DO - 10.1016/S0149-2918(04)90052-5

M3 - Article

VL - 26

SP - 502

EP - 510

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 4

ER -